Timing and duration of omalizumab response in patients

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria Allen Kaplan, MD, Marta Ferrer, MD, Ph. D, Jonathan A. Bernstein, MD, Evgeniya Antonova, MS, Ph. D, Benjamin Trzaskoma, MS, Karina Raimundo, MS, Karin Rosén, MD, Ph. D, Theodore A. Omachi, MD, MBA, Sam Khalil, Ph. D, James L. Zazzali, Ph. D, MPH Journal of Allergy and Clinical Immunology Volume 137 Issue 2 Pages 474 -481 (February 2016) DOI: 10. 1016/j. jaci. 2015. 08. 023 Copyright © 2015 The Authors Terms and Conditions

Fig 1 Journal of Allergy and Clinical Immunology 2016 137474 -481 DOI: (10. 1016/j. jaci. 2015. 08. 023) Copyright © 2015 The Authors Terms and Conditions

Fig 2 Journal of Allergy and Clinical Immunology 2016 137474 -481 DOI: (10. 1016/j. jaci. 2015. 08. 023) Copyright © 2015 The Authors Terms and Conditions

Fig 3 Journal of Allergy and Clinical Immunology 2016 137474 -481 DOI: (10. 1016/j. jaci. 2015. 08. 023) Copyright © 2015 The Authors Terms and Conditions

Fig 4 Journal of Allergy and Clinical Immunology 2016 137474 -481 DOI: (10. 1016/j. jaci. 2015. 08. 023) Copyright © 2015 The Authors Terms and Conditions

Fig 5 Journal of Allergy and Clinical Immunology 2016 137474 -481 DOI: (10. 1016/j. jaci. 2015. 08. 023) Copyright © 2015 The Authors Terms and Conditions